You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. HTS Assays for Modulators of GPCR Signaling

    SBC: Bellbrook Labs, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): More than 50% of drugs on the market target G protein-coupled receptors (GPCRs). Among the most important of these are drugs used to treat neurological disorders, such as pain relievers, antidepressants and anti-psychotics, as well drugs used for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. The relatively recent discovery of a ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. A Microfluidic Chemotaxis High Throughput System

    SBC: Bellbrook Labs, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Neutrophil recruitment is a central component of inflammation, and there is intense focus on inhibiting the process both for chronic inflammatory disorders and for conditions where inflammation plays a contributory role, such as atherosclerosis. Chemotaxis - the movement of cells aligned with a chemical gradient - is the fundamental process underlying neutrophi ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  3. Arrayed Microfluidic Device for Reconstituted Tissue Assays

    SBC: Bellbrook Labs, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): There is a strong need in drug discovery for cellular assays that better predict human responses to drugs. A key technical hurdle has been the difficulty of incorporating complex tissue architecture and cellular microenvironments into an assay format that is compatible with the high throughput approaches used for early drug discovery. In this proposal we propos ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  4. Human Embryonic Stem Cell-Derived Cardiomyocytes for In Vitro Drug Screening

    SBC: CELLULAR DYNAMICS INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Drug-induced QT prolongation is a common cardiac disorder associated with an increased risk for the ventricular arrhythmia torsades de pointes and sudden death. Recognition of this condition has led to increased focus on cardiac toxicity in drug development. The FDA now requires cardiac safety studies prior to drug approval. Since compound development costs a d ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. novel macrolides as anti-infective drugs

    SBC: CENTROSE LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Although it has long been known that macrolide glycosylation is absolutely essential for antibacterial activity, the megalomicins (which differ from erythromycins solely via an additional sugar attached at C6 of the macrolide) were the first macrolides to display notable antiviral and antiparasitic activities. These new activities, unique to the C6-glycosylated ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  6. cardiac neoglycosides as cancer drugs

    SBC: CENTROSE LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Epidemiological evidence points to the value of cardiac glycosides like digoxin and digitoxin for treatment of breast cancer and recent reports suggest they may be especially useful to treat non-small cell lung cancer. These and other findings underlie our belief that a cancer drug could be developed from such natural products. A major need in the development o ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Cytochrome P450 Therapy for Chronic Pain

    SBC: CYTOMETIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have cloned and sequenced a novel cytochrome P450 (CYP) designated CYP4X1. The CYP4X1 mRNA and protein are highly expressed in neurons of the CNS and is ~80% homologous between mouse, rat and human. Recently, we found abundant expression of CYP4X1 in the dorsal root ganglia (DRG). We have identified that CYP4X1 converts arachidonic acid (AA) to the four reg ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  8. Antibiotics from Soil DNA Clone Libraries: Selection of Anti-MRSA Lead Compounds

    SBC: EMETAGEN, LLC.            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of the proposed research is to identify new antibiotic lead compounds with high potential for drug development for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The starting materials are natural product mixtures produced by hit clones previously identified in eMetagen Corporation's large-insert soil metagenomic libraries. T ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  9. HIGH THROUGHPUT CLONING OVEREXPRESSION AND PURIFICATION OF ACTIVE MEMBRANE PROT

    SBC: LUCIGEN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Functional analysis of proteins is essential to thoroughly understand the basic interactions essential for life. However, obtaining pure proteins for basic research and drug screening is limited by technical bottlenecks. For example, high throughput studies are severely hampered by difficulties in producing and detecting active proteins, especially those that a ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Improved DNA Polymerases for Genomic Sequencing

    SBC: LUCIGEN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): This project proposes is that deficiencies in available DNA polymerases increase costs and limit the rate of DNA sequencing and that thermophilic phage DNA polymerases developed here will substantially improve automated fluorescent sequencing, as well as newer technologies being developed. PyroPhage(tm) DNA Polymerases greatly expand the molecular diversity and ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government